• NICE final guidance backs Pfizer's Lorviqua pharmatimes
    May 13, 2020
    The National Institute for Health and Care Excellence (NICE) has published guidance recommending the use of Pfizer's Lorviqua (lorlatinib) for a certain form of lung cancer on the NHS.
PharmaSources Customer Service